Biocept Inc  

(Public, NASDAQ:BIOC)   Watch this stock  
Find more results for BIOC
+0.020 (2.99%)
Real-time:   12:06PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.67 - 0.70
52 week 0.56 - 2.76
Open 0.70
Vol / Avg. 186,883.00/179,934.00
Mkt cap 18.41M
P/E     -
Div/yield     -
EPS -0.96
Shares 24.97M
Beta     -
Inst. own 4%
Aug 2, 2016
Q2 2016 Biocept Inc Earnings Call - 11:00AM EDT - Add to calendar
Aug 2, 2016
Q2 2016 Biocept Inc Earnings Release - 9:30AM EDT - Add to calendar
May 12, 2016
Q1 2016 Biocept Inc Earnings Call - Webcast
May 12, 2016
Q1 2016 Biocept Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -2202.29% -2779.02%
Operating margin -2156.40% -2690.69%
EBITD margin - -2647.83%
Return on average assets -225.18% -197.64%
Return on average equity -1220.81% -976.31%
Employees 42 -
CDP Score - -


5810 Nancy Ridge Dr Ste 150
SAN DIEGO, CA 92121-2840
United States - Map
+1-858-3208200 (Phone)
+1-858-3208225 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Officers and directors

Michael W. Nall President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Mark G. Foletta CPA Interim Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Lyle J. Arnold Ph. D. Senior Vice President - Research & Development, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
Veena Singh M.D. Senior Vice President, Senior Medical Director
Age: 40
Bio & Compensation  - Reuters
Raaj Trivedi Vice President - Commercial Operations
Age: 42
Bio & Compensation  - Reuters
David F. Hale Non-Executive Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
M. Faye Wilson CPA, Lead Independent Director
Age: 77
Bio & Compensation  - Reuters
Marsha A. Chandler Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Bruce E. Gerhardt CPA Independent Director
Age: 63
Bio & Compensation  - Reuters
Bruce A. Huebner Independent Director
Age: 64
Bio & Compensation  - Reuters